TIMM44

Summary

TIMM44 (translocase of inner mitochondrial membrane 44, HGNC:17316) is a protein-coding gene on chromosome 19p13.2, encoding Mitochondrial import inner membrane translocase subunit TIM44 (O43615). Essential component of the PAM complex, a complex required for the translocation of transit peptide-containing proteins from the inner membrane into the mitochondrial matrix in an ATP-dependent manner. It is a selective cancer dependency (DepMap: 88.8% of cell lines).

This gene encodes a peripheral membrane protein associated with the mitochondrial inner membrane translocase, which functions in the import of proteins across the mitochondrial inner membrane and into the mitochondrial matrix. The encoded protein mediates binding of mitochondrial heat shock protein 70 to the translocase of inner mitochondrial membrane 23 (TIM23) complex. Expression of this gene is upregulated in kidney in a mouse model of diabetes. A mutation in this gene is associated with familial oncocytic thyroid carcinoma.

Source: NCBI Gene 10469 — RefSeq curated summary.

At a glance

• Gene–disease (curated): thyroid cancer (Limited, GenCC)
• Clinical variants (ClinVar): 134 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 88.8% of screened cell lines
• MANE Select transcript: NM_006351

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17316
Approved symbol	TIMM44
Name	translocase of inner mitochondrial membrane 44
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	TIM44
Ensembl gene	ENSG00000104980
Ensembl biotype	protein_coding
OMIM	605058
Entrez	10469

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 11 protein_coding, 6 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000270538, ENST00000595565, ENST00000595831, ENST00000595876, ENST00000597926, ENST00000598481, ENST00000598675, ENST00000598968, ENST00000599650, ENST00000599939, ENST00000600000, ENST00000600748, ENST00000870121, ENST00000870122, ENST00000923643, ENST00000923644, ENST00000923645, ENST00000923646, ENST00000957537, ENST00000957538

RefSeq mRNA: 1 — MANE Select: NM_006351 NM_006351

CCDS: CCDS12192

Canonical transcript exons

ENST00000270538 — 13 exons

Exon	Start	End
ENSE00001315547	7943607	7943666
ENSE00003082973	7926718	7927306
ENSE00003468427	7931138	7931188
ENSE00003493387	7935065	7935145
ENSE00003536257	7932840	7932932
ENSE00003544510	7941102	7941197
ENSE00003572157	7928077	7928166
ENSE00003578383	7938027	7938197
ENSE00003601071	7933864	7934003
ENSE00003647413	7933485	7933570
ENSE00003650030	7932627	7932751
ENSE00003664263	7934089	7934238
ENSE00003675207	7927657	7927767

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 96.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 42.9096 / max 305.5722, expressed in 1811 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178923	37.7359	1809
178924	4.4772	1563
178922	0.6965	350

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	96.52	gold quality
gastrocnemius	UBERON:0001388	95.83	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.75	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.57	gold quality
muscle of leg	UBERON:0001383	95.55	gold quality
cerebellar hemisphere	UBERON:0002245	95.55	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.50	gold quality
lower esophagus	UBERON:0013473	95.48	gold quality
cerebellar cortex	UBERON:0002129	95.35	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.27	gold quality
body of uterus	UBERON:0009853	94.95	gold quality
heart left ventricle	UBERON:0002084	94.89	gold quality
right ovary	UBERON:0002118	94.85	gold quality
left ovary	UBERON:0002119	94.85	gold quality
endocervix	UBERON:0000458	94.81	gold quality
mucosa of stomach	UBERON:0001199	94.78	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.75	gold quality
right lobe of thyroid gland	UBERON:0001119	94.67	gold quality
right atrium auricular region	UBERON:0006631	94.61	gold quality
cardiac ventricle	UBERON:0002082	94.48	gold quality
left lobe of thyroid gland	UBERON:0001120	94.31	gold quality
popliteal artery	UBERON:0002250	94.26	gold quality
tibial artery	UBERON:0007610	94.26	gold quality
ectocervix	UBERON:0012249	94.23	gold quality
transverse colon	UBERON:0001157	94.19	gold quality
right lobe of liver	UBERON:0001114	94.10	gold quality
left uterine tube	UBERON:0001303	93.99	gold quality
skin of leg	UBERON:0001511	93.99	gold quality
adenohypophysis	UBERON:0002196	93.87	gold quality
mucosa of transverse colon	UBERON:0004991	93.67	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

5 targeting TIMM44, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-4796-3P	99.08	68.38	1681
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-4535	97.27	65.17	469

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 88.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• This protein has been found differentially expressed in thalami from patients with schizophrenia. (PMID:20471030)
• The Timm44 gene may be a new target for the treatment of type 2 diabetes (PMID:25749183)
• TIM44 was identified for the first time as a potential oncogene, which plays an important role in autophagy through the TIM44-SOD2-ROS-mTOR pathway. (PMID:27849558)
• HuR Promotes Ovarian Cancer Cell Proliferation by Regulating TIMM44 mRNA Stability. (PMID:32901414)
• TIMM44 is a potential therapeutic target of human glioma. (PMID:36438483)
• The mitochondrial protein TIMM44 is required for angiogenesis in vitro and in vivo. (PMID:37147302)
• A first-in-class TIMM44 blocker inhibits bladder cancer cell growth. (PMID:38467612)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	timm44	ENSDARG00000104771
mus_musculus	Timm44	ENSMUSG00000002949
rattus_norvegicus	Timm44	ENSRNOG00000001058
drosophila_melanogaster	CG11779	FBGN0038683
caenorhabditis_elegans	tin-44	WBGENE00020383

Protein

Protein identifiers

Mitochondrial import inner membrane translocase subunit TIM44 — O43615 (reviewed: O43615)

All UniProt accessions (5): O43615, M0QXM9, M0QXU7, M0R124, M0R301

UniProt curated annotations — full annotation on UniProt →

Function. Essential component of the PAM complex, a complex required for the translocation of transit peptide-containing proteins from the inner membrane into the mitochondrial matrix in an ATP-dependent manner. Recruits mitochondrial HSP70 to drive protein translocation into the matrix using ATP as an energy source.

Subunit / interactions. Probable component of the PAM complex at least composed of a mitochondrial HSP70 protein, GRPEL1 or GRPEL2, TIMM44, TIMM16/PAM16 and TIMM14/DNAJC19. The complex interacts with the TIMM23 component of the TIM23 complex. Interacts with SLC25A4/ANT1 and SLC25A5/ANT2; leading to inhibit the presequence translocase TIMM23, thereby promoting stabilization of PINK1.

Subcellular location. Mitochondrion inner membrane. Mitochondrion matrix.

Similarity. Belongs to the Tim44 family.

RefSeq proteins (1): NP_006342* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007379	Tim44-like_dom	Domain
IPR017303	Tim44	Family
IPR032710	NTF2-like_dom_sf	Homologous_superfamily
IPR039544	Tim44-like	Family

Pfam: PF04280

UniProt features (21 total): helix 7, strand 6, modified residue 3, sequence conflict 2, transit peptide 1, chain 1, binding site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2CW9	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43615-F1	64.39	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 166–173

Post-translational modifications (3): 128, 180, 217

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1268020	Mitochondrial protein import

MSigDB gene sets: 159 (showing top): GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, ENK_UV_RESPONSE_KERATINOCYTE_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_PROTEIN_TARGETING, LANG_MYB_FAMILY_TARGETS, TGACCTY_ERR1_Q2, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, BLALOCK_ALZHEIMERS_DISEASE_UP, GOCC_MITOCHONDRIAL_ENVELOPE, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE, RYTTCCTG_ETS2_B, GOBP_PROTEIN_TRANSMEMBRANE_TRANSPORT, GOBP_PROTEIN_LOCALIZATION_TO_MITOCHONDRION, GOBP_PROTEIN_TARGETING_TO_MITOCHONDRION

GO Biological Process (5): obsolete protein targeting to mitochondrion (GO:0006626), intracellular protein transport (GO:0006886), protein import into mitochondrial matrix (GO:0030150), protein transport (GO:0015031), establishment of protein localization (GO:0045184)

GO Molecular Function (4): ATP binding (GO:0005524), protein-folding chaperone binding (GO:0051087), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (6): fibrillar center (GO:0001650), mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), TIM23 mitochondrial import inner membrane translocase complex (GO:0005744), mitochondrial matrix (GO:0005759), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Protein localization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	2
cellular anatomical structure	2
protein transport	1
intracellular transport	1
protein transmembrane import into intracellular organelle	1
protein localization to mitochondrion	1
import into the mitochondrion	1
mitochondrial protein import pathway	1
transport	1
establishment of protein localization	1
establishment of localization	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
nucleolus	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
inner mitochondrial membrane protein complex	1
mitochondrion	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1778 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TIMM44	TIMM17A	Q99595	997
TIMM44	HSPA9	P30036	996
TIMM44	DNAJC19	Q96DA6	996
TIMM44	HSPA4	P34932	991
TIMM44	PAM16	Q9Y3D7	981
TIMM44	GRPEL1	Q9HAV7	971
TIMM44	TIMM50	Q3ZCQ8	941
TIMM44	TOMM70	O94826	916
TIMM44	TIMM21	Q9BVV7	910
TIMM44	TIMM10	P62072	897
TIMM44	TOMM40	O96008	867
TIMM44	TOMM22	Q9NS69	851
TIMM44	TIMM23	O14925	849
TIMM44	DNAJC15	Q9Y5T4	817
TIMM44	TIMM22	Q9Y584	750

IntAct

149 interactions, top by confidence:

A	B	Type	Score
NDUFS3	NDUFS8	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
IGF1R	PIK3R2	psi-mi:“MI:2364”(proximity)	0.590
CMTM5	TIMM44	psi-mi:“MI:0915”(physical association)	0.560
TIMM44	CMTM5	psi-mi:“MI:0915”(physical association)	0.560
TIMM44	UBASH3A	psi-mi:“MI:0915”(physical association)	0.560
TIMM44	CCDC57	psi-mi:“MI:0915”(physical association)	0.560
TIMM44	SFT2D2	psi-mi:“MI:0915”(physical association)	0.560
DR1	TIMM44	psi-mi:“MI:0915”(physical association)	0.560
GTF2B	TIMM44	psi-mi:“MI:0915”(physical association)	0.560
TIMM44	GTF3C3	psi-mi:“MI:0915”(physical association)	0.560
TIMM44	COL1A1	psi-mi:“MI:0914”(association)	0.530
AARS1	TIMM44	psi-mi:“MI:0915”(physical association)	0.400
OPCML	TIMM44	psi-mi:“MI:0915”(physical association)	0.400
EFHC1	TIMM44	psi-mi:“MI:0915”(physical association)	0.400
ARAF	TIMM44	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (294): CMTM5 (Two-hybrid), TIMM44 (Affinity Capture-Western), TIMM44 (Co-fractionation), TIMM44 (Co-fractionation), TIMM44 (Affinity Capture-MS), HSPA9 (Reconstituted Complex), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS), TIMM44 (Affinity Capture-MS)

ESM2 similar proteins: A2RVP7, A2VDV9, A4IFL0, O14925, O35093, O35094, O35857, O43615, O60830, P0CR88, P0CR89, P59670, Q02921, Q2HJE9, Q2KHV4, Q2UAP8, Q38820, Q3B8P0, Q3ZBE6, Q4V8S3, Q5BIN4, Q5M7K0, Q5R5H4, Q5RDD0, Q5REX0, Q5SRD1, Q5U4F4, Q5U4U5, Q5XH94, Q5XJY4, Q5ZLL0, Q6BZY4, Q6GQ39, Q6INU6, Q6NWD4, Q7T2P6, Q86UB9, Q9C1E8, Q9CQ85, Q9CYV5

Diamond homologs: O02161, O35094, O35857, O43615

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
TIMM44	“form complex”	“TIM23 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 133 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
peptidyl-tyrosine phosphorylation	5	17.7×	2e-03
cell surface receptor protein tyrosine kinase signaling pathway	8	11.7×	2e-04
protein autophosphorylation	9	11.0×	1e-04
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	11	7.2×	2e-04
positive regulation of MAPK cascade	9	6.1×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

134 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	79
Likely benign	7
Benign	30

Top pathogenic / likely-pathogenic (0)

SpliceAI

2571 predictions. Top by Δscore:

Variant	Effect	Δscore
19:7927302:TTGTC:T	acceptor_gain	1.0000
19:7927303:TGTC:T	acceptor_gain	1.0000
19:7927304:GTC:G	acceptor_gain	1.0000
19:7927305:TC:T	acceptor_gain	1.0000
19:7927306:CC:C	acceptor_gain	1.0000
19:7927307:C:CC	acceptor_gain	1.0000
19:7927307:C:CG	acceptor_loss	1.0000
19:7927310:C:CT	acceptor_gain	1.0000
19:7927314:G:C	acceptor_gain	1.0000
19:7927314:G:GC	acceptor_gain	1.0000
19:7927695:C:CT	donor_gain	1.0000
19:7927764:CCAG:C	acceptor_gain	1.0000
19:7927765:CAG:C	acceptor_gain	1.0000
19:7927765:CAGC:C	acceptor_gain	1.0000
19:7927768:C:CC	acceptor_gain	1.0000
19:7927780:C:CT	acceptor_gain	1.0000
19:7928075:A:AC	donor_gain	1.0000
19:7928076:C:CC	donor_gain	1.0000
19:7928076:CGT:C	donor_gain	1.0000
19:7931136:A:AC	donor_gain	1.0000
19:7931137:C:CC	donor_gain	1.0000
19:7931137:CAG:C	donor_gain	1.0000
19:7932624:CAC:C	donor_loss	1.0000
19:7932747:GCCCC:G	acceptor_gain	1.0000
19:7932748:CCCC:C	acceptor_gain	1.0000
19:7932748:CCCCC:C	acceptor_gain	1.0000
19:7932749:CCC:C	acceptor_gain	1.0000
19:7932749:CCCC:C	acceptor_gain	1.0000
19:7932750:CC:C	acceptor_gain	1.0000
19:7932750:CCC:C	acceptor_gain	1.0000

AlphaMissense

2966 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:7927234:A:G	W438R	1.000
19:7927234:A:T	W438R	1.000
19:7927279:A:G	W423R	0.999
19:7927279:A:T	W423R	0.999
19:7931152:A:G	W342R	0.999
19:7931152:A:T	W342R	0.999
19:7927230:C:G	R439P	0.998
19:7927730:A:G	L389P	0.998
19:7932670:A:G	F315S	0.998
19:7938077:C:G	A88P	0.998
19:7927232:C:A	W438C	0.997
19:7927232:C:G	W438C	0.997
19:7927236:G:T	A437D	0.997
19:7931147:G:C	C343W	0.997
19:7931149:A:G	C343R	0.997
19:7931188:C:G	A330P	0.997
19:7933917:T:A	R210S	0.997
19:7933917:T:G	R210S	0.997
19:7933918:C:G	R210T	0.997
19:7927233:C:G	W438S	0.996
19:7927272:A:G	L425P	0.996
19:7927733:A:T	V388E	0.996
19:7927757:C:T	G380D	0.996
19:7927758:C:G	G380R	0.996
19:7931160:A:T	L339H	0.996
19:7932631:A:G	L328P	0.996
19:7932659:A:G	C319R	0.996
19:7932684:A:C	F310L	0.996
19:7932684:A:T	F310L	0.996
19:7932686:A:G	F310L	0.996

dbSNP variants (sampled 300 via entrez): RS1000107836 (19:7935184 T>C), RS1000211943 (19:7929453 C>T), RS1000558560 (19:7928414 T>C), RS1000583562 (19:7943549 T>C,G), RS1000748715 (19:7937835 T>C), RS1000884394 (19:7943441 C>A,T), RS1000936266 (19:7943662 C>A,G,T), RS1001687548 (19:7933739 G>A,C), RS1001807507 (19:7939194 T>C,G), RS1001886298 (19:7944541 G>A), RS1001886873 (19:7928963 C>A,G,T), RS1001911361 (19:7929285 G>A), RS1001938849 (19:7944836 G>A), RS1002066 (19:7945050 A>G), RS1002153523 (19:7938926 G>T)

Disease associations

OMIM: gene MIM:605058 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
thyroid cancer	Limited	Autosomal dominant

Mondo (1): thyroid cancer (MONDO:0002108)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066349 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.51	Kd	309.9	nM	CHEMBL5653589
6.51	ED50	309.9	nM	CHEMBL5653589
6.35	Kd	445	nM	CHEMBL3752910
6.35	ED50	445	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149589: Binding affinity to human TIMM44 incubated for 45 mins by Kinobead based pull down assay	kd	0.3099	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149589: Binding affinity to human TIMM44 incubated for 45 mins by Kinobead based pull down assay	kd	0.4450	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	affects cotreatment, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment, decreases expression	2
Leflunomide	decreases expression	2
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Tunicamycin	increases expression	2
Valproic Acid	affects expression, increases methylation	2
Thapsigargin	decreases expression, increases expression	2
Particulate Matter	affects cotreatment, increases abundance, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
alpha-pinene	increases abundance, affects cotreatment, decreases expression, increases oxidation	1
bisphenol A	affects expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
aflatoxin B2	increases methylation	1
methacrylaldehyde	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
perfluoro-n-nonanoic acid	increases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Sunitinib	increases expression	1
Acetaminophen	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
Air Pollutants	increases oxidation, affects cotreatment, decreases expression, increases abundance	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652631	Binding	Binding affinity to human TIMM44 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00604318	PHASE4	COMPLETED	Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
NCT01496313	PHASE4	COMPLETED	To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
NCT02946918	PHASE4	TERMINATED	Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy
NCT03065218	PHASE4	TERMINATED	99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients
NCT03469310	PHASE4	COMPLETED	Minimizing Narcotic Analgesics After Endocrine Surgery
NCT03969108	PHASE4	COMPLETED	Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment
NCT06697782	PHASE4	COMPLETED	Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer
NCT07600580	PHASE4	ACTIVE_NOT_RECRUITING	The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response
NCT00410761	PHASE3	COMPLETED	An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
NCT00435851	PHASE3	UNKNOWN	Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
NCT00704730	PHASE3	COMPLETED	Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
NCT00794053	PHASE3	COMPLETED	The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer
NCT00795782	PHASE3	COMPLETED	Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
NCT01321554	PHASE3	COMPLETED	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
NCT03570021	PHASE3	ACTIVE_NOT_RECRUITING	ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
NCT04290663	PHASE3	RECRUITING	Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
NCT05468554	PHASE3	UNKNOWN	Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
NCT05999630	PHASE3	RECRUITING	Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
NCT06082180	PHASE3	RECRUITING	A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer
NCT06554652	PHASE3	RECRUITING	Selective Neck Dissection Versus Modified Neck Dissection in PTC
NCT06558981	PHASE3	RECRUITING	Adjuvant Radiotherapy in High Risk Locally Advanced DTC
NCT06860971	PHASE3	RECRUITING	A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT00080574	PHASE2	COMPLETED	The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients
NCT00085293	PHASE2	COMPLETED	Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
NCT00095693	PHASE2	TERMINATED	Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
NCT00098345	PHASE2	COMPLETED	Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
NCT00098813	PHASE2	COMPLETED	Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
NCT00104871	PHASE2	COMPLETED	Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT00115739	PHASE2	TERMINATED	Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
NCT00118248	PHASE2	COMPLETED	Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
NCT00121628	PHASE2	COMPLETED	A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
NCT00124527	PHASE2	COMPLETED	Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
NCT00126568	PHASE2	TERMINATED	Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT00134043	PHASE2	COMPLETED	Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
NCT00176748	PHASE2	COMPLETED	Treatment for Patients With Metastatic Thyroid Cancer
NCT00181168	PHASE2	COMPLETED	Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
NCT00251316	PHASE2	COMPLETED	Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
NCT00358956	PHASE2	COMPLETED	A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
NCT00519896	PHASE2	COMPLETED	Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
NCT00784303	PHASE2	COMPLETED	Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology